Polycystic Ovarian Disease Predisposes Young Women To Heart Disease.

"These findings underscore the need to screen and aggressively counsel and treat these women to prevent symptomatic cardiovascular disease."

Dr. Rupal Shroff and colleagues.

Journal of Clinical Endocrinology and Metabolism. (December 2007 issue).

University of Iowa, Iowa City.

Polycystic ovarian disease is common among young women, especially when they are obese. This disease can lead to high blood pressure, increased cholesterol and predisposition to diabetes mellitus. Dr. Rupal and his colleagues studied women, 21 to 50 years with polycystic ovarian disease. They found that a third of the women had early onset of heart disease (coronary heart disease). Most of these women did not have any risk factors for heart disease. Though the number of patients involved in this study is small, it appears that polycystic ovarian disease is by itself a risk factor for coronary heart disease and hence healthcare providers should diagnose this disease early and treat it to prevent its complications.

Depot Provera Injection Induced Bone Density Loss Recovers After Discontinuation.

Depot Provera is a commonly used contraceptive method by women in the childbearing age. In 2004, the FDA raised concerns about the loss on bone in women who use the medication for a prolonged period. Many South African women use this type of contraception. A recent study was done on South African women who used Depot Provera and Norethindrone (given by injection and is similar to Depot Provera). Bone loss measurement by ultrasound showed loss of bone that was worse in women who used the medications for ten years or more. The good news is that when the women discontinued the injections, the loss of bone recovered within 2 years.

This is good news for women who are using this medication to prevent pregnancy. There is hope that when they discontinue the injections their bone loss recover. This should give assurance to caregivers and women to continue using this effective and convenient hormonal contraceptive method.

Reference: Bone status after cessation of use of injectable progestin contraceptives. Rosenberg et al.